On Thursday, Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30.

The orthopedic giant reported sales of $2.02 billion, up 4.3% on a reported basis (+4.9% on constant currency), beating the consensus of $2.014 billion.

Knee product sales increased 5.1% to $839.2 million, and hip product sales increased 3% (+4% on constant currency) to $520 million.

Sports Medicine products generated sales of $489.4 million, up 8% (+8.4%).

"We have committed to diversifying our portfolio outside of core orthopedics and investing in attractive, higher-growth segments. Our recently announced agreement to acquire Paragon 28 marks a bold step towards executing on our diversification ambitions; once the transaction is closed, we expect our S.E.T. business to be larger than our Hip business, and to grow at a much faster pace," said Ivan Tornos, Zimmer Biomet's President and CEO.

Operating margin improved to 19.2% from 18.3%.

Recently, Zimmer Biomet agreed to acquire Paragon 28, Inc. (NASDAQ:FNA) for an upfront cash payment of $13.00 per share, corresponding to an equity value of approximately $1.1 billion and an enterprise value of approximately $1.2 billion.

Paragon 28 shareholders will also receive a contingent value right, which entitles the holder to up to $1.00 per share in cash if certain revenue milestones are achieved.

Guidance: Zimmer Biomet expects fiscal year 2025 adjusted EPS of $8.15-$8.35 versus consensus of $8.55. The company expects 2025 revenue growth of 1%-3.5%.

Price Action: ZBH stock is down 3.13% at $104.86 at last check Thursday.

Read Next:

• AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China